Related references
Note: Only part of the references are listed.Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura et al.
JCO PRECISION ONCOLOGY (2018)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Therapeutic options for intrahepatic cholangiocarcinoma
Manojkumar Bupathi et al.
HEPATOBILIARY SURGERY AND NUTRITION (2017)
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K. P. Papadopoulos et al.
BRITISH JOURNAL OF CANCER (2017)
E7090, a novel and selective FGFR inhibitor, for the treatment of cholangiocarcinoma cells harboring FGFR2-fusion genes
Saori W. Miyano et al.
CANCER RESEARCH (2017)
Treating Hepatobiliary Cancers: The Oncology Way
Peter Robert Galle
DIGESTIVE DISEASES (2017)
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeted therapy in biliary tract cancers-current limitations and potentials in the future
Selley Sahu et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini et al.
CLINICAL CANCER RESEARCH (2016)
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
Apurva Jain et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence G. Hall et al.
PLOS ONE (2016)
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
Mitesh J. Borad et al.
CURRENT OPINION IN GASTROENTEROLOGY (2015)
Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
Leandro H. Gallo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Daniela Sia et al.
NATURE COMMUNICATIONS (2015)
Fibroblast Growth Factor Receptor 2 (FGFR2) Is Required for Corneal Epithelial Cell Proliferation and Differentiation during Embryonic Development
Jinglin Zhang et al.
PLOS ONE (2015)
Second-line chemotherapy in advanced biliary cancer: a systematic review
A. Lamarca et al.
ANNALS OF ONCOLOGY (2014)
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Bernard Escudier et al.
CLINICAL CANCER RESEARCH (2014)
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Alexandra R. Grassian et al.
CURRENT OPINION IN GASTROENTEROLOGY (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Rondell P. Graham et al.
HUMAN PATHOLOGY (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad et al.
PLOS GENETICS (2014)
Intrahepatic Cholangiocarcinoma: Management Options and Emerging Therapies
Rebecca M. Dodson et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2013)
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp et al.
HUMAN PATHOLOGY (2012)
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee et al.
LANCET ONCOLOGY (2012)
Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23-Klotho System
Chung-Yi Cheng et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
T Shimada et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Share Paper
